国际皮肤性病学杂志    2001 27 (6): 339-341   ISSN: 2096-5540  CN: 32-1880/R   银屑病的抗体治疗概况 王刚综述, 李春英综述, 刘玉峰审校 第四军医大学西京医院皮肤科 收稿日期 null  修回日期 null  网络版发布日期 null 参考文献  [1] Winter G,Harris WJ.Humanized antibodies.Immunol Today,1993,14(6):243-246. [2] Ryu DD,Nam DH.Recent progress in biomolecular engineering.Biotechnol Prog,2000,16(1):2-16. [3] Hoogenboom HR,de Bruine AP,Hufton SE,et al.Antibody phage display technology and its applications.Immunotechnology,1998,4(1):1-20. [4] Knappik A,Ge L.Honegger A,et al.Fully synthetic human combinatorialantibody libraries(HuCAL) based on modular consensus frameworks andCDRs randomized with trinucleotides.J Mol Biol,2000,296(1):57-86. [5] Lonlerg N.Huszgr D.Human antibodies from transgenic mice.Int Rev Immunol,1995,13(1):65-93. [6] Robinet E,Stamm C,Nicolas JF,et al.CD4 monoclonal antibody adminis-tration in atopic dermatitis.J Am Acad Dermatol,1997,36(4):582-588. [7] Bachelez H,Flageul B,Dubertret L,et al.Treatment of recalcitrant plaquepsoriasis with a humanized non-depleting antibody to CD4.J Autoimmun,1998.11(1):53-62. [8] Owen CM.Harrison PV.Successful treatment of severe psoriasis with basil-tximab.an interleukin-2 receptor monoclonal antibody.Clin Exp Derma-tol.2000.25(3):195-197. [9] Mrowietz U,Zhu KJ,Christophers E.Treatment of severe psoriasis with an-ti-CD2 monoclonal antibodies.Arch Dermatol,2000,136(5):675-676. [10] Krueger JG,Walters IB,Miyazawa M,et al.Successful in vivo blockade of CD25(high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis.J Am Acad Derma-tol,2000,43(3):448-458. [11] Wohlrab J,Fischer M.Taube K,et al.Treatment of recalcitrant psoriasiswith daclizumab.Br J Dermatol,2001,144(1):209-210. [12] Oh CJ.Das KM,Gottlieb AB.Treatment with anti-tumor necrosis factor o(TNFα) monoclonal antibody dramatically decreases the clinical activity ofpsoriasis lesions.J Am Acad Dermatol,2000,42 (5Pt 1):829-830. [13] Kirby B,Mairsland AM,Carmichael AJ,et al.Successful treatment of se vere recalcitrant psoriasis with combination infliximab and methotrexate.Clin Exp Dermatol,2001,26(1):27-29. [14] Ogilvie AL,Antoni C,Dechant C,et al.Treatment of psoriatic arthuitiswith antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate.Br J Dermatol.2001,144 (3):587-589. [15] Gottlieb A,Krueger JG,Bright R,et al.Effects of administration of a sin-gle dose of a humanized monoclonal antibody to CD1 1a on the immunobiol ogy and clinical activity of psoriasis.J Am Acad Dematol,2000,42(3):428-435. [16] Nickoloff BJ,Mitra RS,Varani J,et al.Aberrant production of inter-leukin-8 and thrombospondin-1 by psoriatic keratinocytes mediates angio-genesis.Am J Pathol,1994,144(4):820-828. [17] Hong K,Chu A,Ludviksson BR,et al.IL-12,independently of IFN-gam-ma,plays a crucial role in the pathogenesis of a murine psoriasis-like skindisorder.J Immunol,1999,162 (12):7480-7491. [18] Ogata A,Nishimoto N,Yoshizaki K.Advances in interleukin-6 therapy.Rinsho Byori,1999,47(4):321-326. [19] Montero E,Falcon L,Morera Y,et al.CD6 molecule may be important in the pathological mechanisms of lymphocytes adhesion to human skin in pso-riasis and ior t1 MAb a possible new approach to treat this disease.Autoimmunity,1999,29(2):155-156. 通讯作者: